# A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

Source: https://onco.cc/trials/nct04685226/  
OnCo record `nct04685226` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ICP-723 in advanced solid tumours, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.

## Summary

A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04685226 by Beijing InnoCare Pharma Tech Co., Ltd., with 310 participants planned, started 2020-09-27 and due to reach its primary completion in 2028-01-25. Interventions recorded: ICP-723.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04685226
- Phase: 1/2
- Setting: A Multicenter, Nonrandomized, Open-Label Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Solid Tumors
- Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
- Enrolled: 310

## Sources

- ClinicalTrials.gov NCT04685226: https://clinicaltrials.gov/study/NCT04685226

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct04685226.json